This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in August 2014.
Deal of the month
Acquisition agreement for Intermune
Aug 25, 2014 - Roche, Intermune
Roche announced the acquisition of Brisbane, California biotech company InterMune, Inc. for a cash transaction totaling $8.3 billion.......more
Breaking news...
Grant award for $861m for therapeutic targets research
Aug 26, 2014 - University of Colorado and collaborators
University of Colorado faculty researchers attracted $861.04 million in research awards in the 2013-14 fiscal year......more
For more breaking deals as they are announced, visit:http://www.currentagreements.com
August 2014 has been a fairly busy month with the announcements of high value and big pharma deals bringing the total number of deals for the month to 207. The top partnering deal by value was the asset purchase agreement for health information technology between Siemens and Cerner worth $USD 1.3bn. Further details can be viewed here.
On the M&A front, 32 deals with very high values were announced; the leading deal was the acquisition of Intermune by Roche in a deal valued at $USD 8.3bn. Further details can be viewed here.
On the financings front we recorded 99 announcements, with the leading deal by value being the loan financing for $700m by Cooper Companies. Further details can beviewed here.
Our sister company, Current Partnering published several new and updated reports:
- Discovery Stage Partnering Terms and Agreements
- Preclinical Stage Partnering Terms and Agreements
- Clinical Stage Partnering Terms and Agreements
View our full list of reports here at our report store.
Our Current Partnering website showcases the leading partnering, M&A and financing deals by value.
To see all of 2014 leading deals and view the full set of Scorecards for 2014, visit Partnering scorecard | M&A scorecard | Financing scorecard - check them out.
We welcome your comments and feedback on this newsletter. We are also interested in hearing from any company with a deal not announced by press release; this allows us to add further non-publicized deals to the database.
Best regards,
Shamini Thiagarajan
Top ten deal analysis of the month by deal value
The following are the top 10 partnering deals and alliances by value, as announced in August 2014
1. Asset purchase agreement for health information technology - Cerner, Siemens - $1.3bn
2. Collaboration and licensing agreement for Afrezza Inhalation powder- MannKind Biopharmaceuticals, Sanofi- $925m
3. Grant award for $861.04 million for research- American Heart/Stroke Association, Department of Health and Human Services, National Institutes of Health, National Science Foundation, University of Colorado, University of Colorado Denver- $861.04m
4. Collaboration agreement for developing hydrocodone combination products- Charleston Laboratories, Daiichi Sankyo - $650m
5. Collaboration agreement for LiRIS program - Allergan, TARIS Biomedical- $587.5m
6. Asset purchase agreement for OEM Solutions business segment - Symmetry Medical, Tecomet - $450m
7. Co development and licensing agreement for ES414 - Emergent BioSolutions, MorphoSys - $183m
8. Licensing, development and marketing agreement for therapeutic agents to treat food allergy - Immune Design, Sanofi-Aventis - $168m
9. Asset purchase agreement for equity interest - Guiyang Dalin Biotechnology, Guizhou Taibang Biological Products- $87.1m
10. Development agreement for clinical development of QR-010 - Cystic Fibrosis Foundation Therapeutics, ProQR Therapeutics - $86m
Full details of each deal available at Current Agreements*
*Subscription required
Big pharma deal analysis August 2014
August saw 36 partnering deals announced with big pharma being at least one of the parties of the deal.
Sanofi were particularly active, leading partnering activities in August.
Sanofi partnering- August 2014
- Collaboration agreement for developing oncology sequencing technology - with AstraZeneca, Illumina, Janssen Biotech
- Collaboration and licensing agreement for Afrezza Inhalation powder - with MannKind Biopharmaceuticals
- Licensing, development and marketing agreement for therapeutic agents to treat food allergy -with Immune Design
- Marketing and distribution agreement for oncology portfolio - with Immune Design
Sanofi partnering report
Further details of all big pharma deals are available at Current Agreements.
Big biotech deal analysis August 2014
August saw 9 partnering deals announced with big biotech being at least one of the parties of the deal.
Celgene were particularly active, leading partnering activity in August.
Celgene partnering - August 2014
- Evaluation agreement for OPDIVO (nivolumab) and ABRAXANE (paclitaxel protein-bound particles for injectable suspension) - with Bristol-Myers Squibb
- Licensing, development and co-promotion agreement for PSC-100 - with Human Longevity
Celgene partnering report
Further details of all big pharma deals are available at Current Agreements.
Current Agreements products
CP Knowledge Centre : Access the best of Current Partnering and Current Agreements with a CP Knowledge Center subscription. Buy now
